Ergotism, a relatively unknown mimic of vasculitis: A case report and review of literature / Ergotismo: un imitador poco conocido de vasculitis. Reporte de caso y revisión de la literatura

ABSTRACT Introduction: Ergotism is a vasospasm that affects visceral and peripheral muscle arteries. Classically, symmetrical involvement of lower limb arteries is described, and is often associated with a history of chronic consumption of ergotamine derived medications (Cafergot). Case report: A 22 year-old healthy man with infectious mononucleosis syndrome, who presented with a sudden onset of paraesthesias in the lower limbs, as well as livedo reticularis. The initial diagnosis was a medium-sized vessel vasculitis (polyarteritis nodosa). The symptoms were preceded by the administration of Cafergot for headache treatment, and resolved spontaneously. The magnetic resonance angiography (MRA) of the lower limbs showed occlusion of peroneal arteries, with filiform distal flow. Other infectious, autoimmune and cardiovascular origins were ruled out. Discussion: Ergotism is an important differential diagnosis in the study of the patient with vasculitis, especially in acute onset presentations. Its treatment is the suspension of the causal drug, with vasodilator and surgical vascular procedures, if necessary. Conclusions: Ergotism is an imitator of vasculitis, especially in young patients with a history of difficult to control migraine. The concomitant administration of CYP3A4 inhibitors (mainly, protease inhibitors and macrolides) enhances the toxic effects of ergot.

RESUMEN Introducción: El ergotismo es un vasoespasmo que afecta las arterias musculares periféricas y viscerales. Clásicamente se describe la afectación simétrica de las arterias de las extremidades inferiores, a menudo asociada con el consumo crónico de medicamentos derivados de ergotamina (Cafergot®). Caso clínico: Varón sano de 22 anos con síndrome de mononucleosis, presentó parestesias en las extremidades inferiores y livedo reticularis de forma súbita, el diagnóstico inicial fue una vasculitis de mediano vaso (poliarteritis nodosa). Los síntomas fueron precedidos por la administración de Cafergot® para el tratamiento de cefalea, y se resolvieron espontáneamente. La angiografía por resonancia magnética (ARM) de las extremidades inferiores mostró oclusión de las arterias peroneas, con flujo distal filiforme. Se descartaron otras etiologías infecciosas, autoinmunes y cardiovasculares. Discusión: Los ergotismos son un diagnóstico diferencial importante en el estudio del paciente con vasculitis, especialmente en presentaciones de inicio agudo. Su tratamiento es la suspensión del fármaco causal, vasodilatadores y procedimientos vasculares quirúrgicos, si es necesario. Conclusiones: El ergotismo es un imitador de vasculitis, especialmente en pacientes jóvenes con antecedentes de migrana de difícil control. La administración concomitante de inhibidores del CYP3A4 (principalmente, inhibidores de proteasa y macrólidos) potencia los efectos tóxicos del ergot.

Vértigo como presentación clínica de asa vascular de la arteria cerebelosa antero inferior / Vertigo as a clinical presentation of a vascular loop of the anterior inferior cerebellar artery

Resumen El vértigo es un frecuente motivo de consulta cuyo origen puede ser periférico o central; causas poco frecuentes de este último son las asas vasculares que afectan el VIII par craneal llevando a acúfenos, pérdida de la audición y mareo. Se presenta una mujer de 47 años de edad, quien consulta por un cuadro de mareo, náuseas, pérdida del tono postural, cefalea y parestesia facial, cuyo examen físico revela signos de vértigo periférico, iniciándose tratamiento con antieméticos, anticinetósicos y vasodilatadores que llevan a empeoramiento del cuadro, por lo que se sospecha de patología a nivel de sistema nervioso central (SNC) que ejerce compresión con la vasodilatación. Se realiza una resonancia magnética que muestra un asa vascular en la arteria cerebelosa inferior anterior (AICA) que ingresa al conducto auditivo interno (CAI) explicando la sintomatología y cuyo efecto compresivo de los nervios centrales genera un efecto paradójico con la toma de vasodilatadores. (Acta Med Colomb 2018; 43: 226-229).

Abstract Vertigo is a frequent reason for consultation whose origin can be peripheral or central; infrequent causes of the latter are the vascular loops that affect the VIII cranial nerve leading to tinnitus, hearing loss and dizziness. The case of a 47-year-old woman who consulted for a picture of dizziness, nausea, loss of postural tone, headache and facial paraesthesia, and whose physical examination revealed signs of peripheral vertigo, is presented. Treatment was started with antiemetics, anticinetics and vasodilators that lead to worsening of the condition, for which pathology exerting compression due to vasodilation at the central nervous system (CNS) level, is suspected. An MRI is performed showing a vascular loop in the Anterior Lower Cerebellar Artery (AICA) that enters the Internal Auditory Canal (IAC) explaining the symptomatology and whose compressive effect of the central nerves generates a paradoxical effect with the taking of vasodilators. (Acta Med Colomb 2018; 43: 226-229).

Extracts of Crataegus oxyacantha and Rosmarinus officinalis Attenuate Ischemic Myocardial Damage by Decreasing Oxidative Stress and Regulating the Production of Cardiac Vasoactive Agents.

Numerous studies have supported a role for oxidative stress in the development of ischemic damage and endothelial dysfunction. Crataegus oxyacantha (Co) and Rosmarinus officinalis (Ro) extracts are polyphenolic-rich compounds that have proven to be efficient in the treatment of cardiovascular diseases. We studied the effect of extracts from Co and Ro on the myocardial damage associated with the oxidative status and to the production of different vasoactive agents. Rats were assigned to the following groups: (a) sham; (b) vehicle-treated myocardial infarction (MI) (MI-V); (c) Ro extract-treated myocardial infarction (MI-Ro); (d) Co extract-treated myocardial infarction (MI-Co); or (e) Ro+Co-treated myocardial infarction (MI-Ro+Co). Ro and Co treatments increased total antioxidant capacity, the expression of superoxide dismutase (SOD)-Cu2+/Zn2+, SOD-Mn2+, and catalase, with the subsequent decline of malondialdehyde and 8-hydroxy-2'-deoxyguanosine levels. The extracts diminished vasoconstrictor peptide levels (angiotensin II and endothelin-1), increased vasodilators agents (angiotensin 1-7 and bradikinin) and improved nitric oxide metabolism. Polyphenol treatment restored the left intraventricular pressure and cardiac mechanical work. We conclude that Ro and Co treatment attenuate morphological and functional ischemic-related changes by both an oxidant load reduction and improvement of the balance between vasoconstrictors and vasodilators.

Potential pharmacological use of salivary compounds from hematophagous organisms / Uso potencial farmacológico de los compuestos salivares de organismos hematófagos

Abstract Introduction: The saliva of hematophagous or blood-sucking insects contains different substances that allow obtaining and ingesting the blood of their vertebrate hosts without being detected. Objective: To explore the salivary compounds of hematophagous insects which have vasodilator, anticoagulant, anti-inflammatory, immunomodulatory and anesthetic properties, and that can be exploited due to their high pharmacological potential. Materials and methods: A non-systematic literature review was done in PubMed, EMBASE, and ScienceDirect OvidSP; data was not limited by date, language nor item type. Articles on salivary compounds of blood-sucking insects, whose main topic was the effects on hemostasis, immunomodulation and drug use, were sought. 59 articles met the criteria for inclusion in the review. Conclusions: The saliva of hematophagous insects has a wide variety of molecules that constitute a source of research and have an incalculable potential for the discovery of compounds that could be pharmacologically useful.

Resumen Introducción. La saliva de los artrópodos hematófagos contiene un arsenal de compuestos que les permite acceder a la sangre de sus hospederos vertebrados sin ser detectados. Objetivo. Explorar los compuestos salivares de insectos hematófagos que tienen propiedades vasodilatadoras, anticoagulantes, antiinflamatorias, inmunomoduladoras y anestésicas, las cuales se pueden aprovechar por su alto potencial farmacológico. Materiales y métodos. Se realizó una revisión no sistemática de la literatura mediante búsqueda electrónica en las bases de datos PubMed, EMBASE, OvidSP y ScienceDirect; la búsqueda no se limitó por fecha, idioma ni tipo de artículo. Se buscaron artículos sobre los compuestos salivares de los insectos hematófagos, cuyo tema central fuese los efectos en la hemostasia, inmunomodulación y uso farmacológico. Se encontraron 59 artículos que cumplían con los criterios para ser incluidos en la revisión. Conclusión. La saliva de los insectos hematófagos posee gran variedad de moléculas, lo que ofrece una fuente de investigación y un potencial incalculable para el descubrimiento de compuestos que podrían llegar a tener utilidad farmacológica.

Validation of an instrument regarding nursing intervention in patients in vasoactive therapy / Validación de instrumentos para intervención de la enfermería en el paciente pasando por terapia vasoactiva / Validação de instrumento para intervenção de enfermagem ao paciente em terapia vasoativa

ABSTRACT Objective: to validate the content of a Standard Operational Procedure, regarding nursing interventions in emergency patients treated with vasoactive drugs. Method: methodological study, carried out from December 2015 to January 2016. Content validity was determined by 16 experts (13 nurses, 2 pharmacists and one biomedical scientist), who judged it through a four-point Likert scale. The items were evaluated in terms of: feasibility, objectivity, simplicity, clearness, pertinence and accuracy. The Content Validity Index was applied, accepting the value ≥ 0.90. Results: two rounds of evaluation were required to achieve the minimum index. The items were reviewed regarding writing, dilution, indication and replacement interval. The instrument was validated with 33 items and with total Content Validity Index of 0.99. Conclusion: the instrument was considered appropriate, fractionally and globally, for nursing care for the patient treated with vasoactive drugs in emergency, in a safe and reliable way.

RESUMEN Objetivo: validar el contenido del Procedimiento Operacional Estándar para la intervención de la enfermería en el paciente que usa fármacos vasoactivos en la emergencia. Método: estudio metodológico, realizado entre diciembre de 2015 y enero de 2016. La validación del contenido fue determinada mediante la escala tipo Likert de cuatro puntos por 16 jueces, de los cuales 13 eran enfermeros, dos farmacéuticos y uno biomédico. Los apartados se clasificaron en: ejecutabilidad, objetividad, simplicidad, claridad, pertinencia y precisión. Se aplicó el Índice de Validez de Contenido con la aceptación del valor ≥ 0,90. Resultados: se necesitaron dos rondas de validación para alcanzar el índice. Los apartados se alteraron en la redacción, la dilución, la indicación y el intervalo de cambio. El instrumento se validó con 33 tópicos y con Índice de Validez del Contenido total de 0,99. Conclusión: los resultados se consideran adecuados separadamente, y de manera global, para que el enfermero cuide del paciente usuario de fármacos vasoactivos de forma segura y confiable en la emergencia.

RESUMO Objetivo: validar o conteúdo do Procedimento Operacional Padrão, para intervenção de enfermagem ao paciente em uso de fármacos vasoativos na emergência. Método: estudo metodológico, realizado de dezembro de 2015 a janeiro de 2016. A validação de conteúdo deu-se por 16 juízes, sendo 13 enfermeiros, dois farmacêuticos e um biomédico, que o julgaram por meio da escala tipo Likert de quatro pontos. Os itens foram avaliados em: exequibilidade, objetividade, simplicidade, clareza, pertinência e precisão. Aplicou-se o Índice de Validade de Conteúdo, aceitando-se o valor ≥ 0,90. Resultados: foram necessárias duas rodadas de validação para atingir o índice. Os itens foram alterados: na redação, diluição, indicação, intervalo de troca. O instrumento foi validado com 33 itens e com Índice de Validade de Conteúdo total de 0,99. Conclusão: considerou-se adequado, separadamente, e de maneira global, para que o enfermeiro possa cuidar do paciente em uso de fármacos vasoativos na emergência, de forma segura e confiável.

Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.

BACKGROUND: Wave reflections, which are increased in patients with heart failure with preserved ejection fraction, impair diastolic function and promote pathologic myocardial remodeling. Organic nitrates reduce wave reflections acutely, but whether this is sustained chronically or affected by hydralazine coadministration is unknown. METHODS AND RESULTS: We randomized 44 patients with heart failure with preserved ejection fraction in a double-blinded fashion to isosorbide dinitrate (ISDN; n=13), ISDN+hydralazine (ISDN+hydral; n=15), or placebo (n=16) for 6 months. The primary end point was the change in reflection magnitude (RM; assessed with arterial tonometry and Doppler echocardiography). Secondary end points included change in left ventricular mass and fibrosis, measured with cardiac magnetic resonance imaging, and the 6-minute walk distance. ISDN reduced aortic characteristic impedance (mean baseline=0.15 [95% CI, 0.14-0.17], 3 months=0.11 [95% CI, 0.10-0.13], 6 months=0.10 [95% CI, 0.08-0.12] mm Hg/mL per second; P=0.003) and forward wave amplitude (Pf, mean baseline=54.8 [95% CI, 47.6-62.0], 3 months=42.2 [95% CI, 33.2-51.3]; 6 months=37.0 [95% CI, 27.2-46.8] mm Hg, P=0.04), but had no effect on RM (P=0.64), left ventricular mass (P=0.33), or fibrosis (P=0.63). ISDN+hydral increased RM (mean baseline=0.39 [95% CI, 0.35-0.43]; 3 months=0.31 [95% CI, 0.25-0.36]; 6 months=0.44 [95% CI, 0.37-0.51], P=0.03), reduced 6-minute walk distance (mean baseline=343.3 [95% CI, 319.2-367.4]; 6 months=277.0 [95% CI, 242.7-311.4] meters, P=0.022), and increased native myocardial T1 (mean baseline=1016.2 [95% CI, 1002.7-1029.7]; 6 months=1054.5 [95% CI, 1036.5-1072.3], P=0.021). A high proportion of patients experienced adverse events with active therapy (ISDN=61.5%, ISDN+hydral=60.0%; placebo=12.5%; P=0.007). CONCLUSIONS: ISDN, with or without hydralazine, does not exert beneficial effects on RM, left ventricular remodeling, or submaximal exercise and is poorly tolerated. ISDN+hydral appears to have deleterious effects on RM, myocardial remodeling, and submaximal exercise. Our findings do not support the routine use of these vasodilators in patients with heart failure with preserved ejection fraction. CLINICAL TRIAL REGISTRATION: URL: www.clinicaltrials.gov. Unique identifier: NCT01516346.

Iloprost inhalado, un vasodilatador pulmonar selectivo. Evidencia clínica de su uso en la hipertensión pulmonar del perioperatorio de cirugía cardiovascular / Inhaled iloprost, a selective pulmonary vasodilator. Clinical evidence from its use in perioperative pulmonary hypertension cardiovascular surgery

El iloprost inhalado es uno de los fármacos más recientes del grupo de prostanoides en el tratamiento de la hipertensión arterial pulmonar. No se ha definido su importancia en la hipertensión pulmonar en el perioperatorio de cirugía cardiovascular. En esta revisión se analizan los grupos con hipertensión pulmonar susceptibles de cirugía cardiaca, la importancia de la hipertensión pulmonar en cirugía cardiaca y, además, la evidencia clínica actual del uso del fármaco en este contexto.

Inhaled iloprost is one of the most recent drugs from prostanoids group's in the treatment of pulmonary arterial hypertension. His place in pulmonary hypertension seen in the perioperative cardiovascular surgery has not been defined. In this review we analyze pulmonary hypertension group's susceptibles of cardiac surgery and its importance, besides the current clinical evidence from drug use in this context.

[Inhaled iloprost, a selective pulmonary vasodilator. Clinical evidence from its use in perioperative pulmonary hypertension cardiovascular surgery]. / Iloprost inhalado, un vasodilatador pulmonar selectivo. Evidencia clínica de su uso en la hipertensión pulmonar del perioperatorio de cirugía cardiovascular.

Inhaled iloprost is one of the most recent drugs from prostanoids group's in the treatment of pulmonary arterial hypertension. His place in pulmonary hypertension seen in the perioperative cardiovascular surgery has not been defined. In this review we analyze pulmonary hypertension group's susceptibles of cardiac surgery and its importance, besides the current clinical evidence from drug use in this context.

Utilidad clínica del iloprost inhalado en la hipertensión arterial pulmonar / Clinical utility of inhaled iloprost in pulmonary arterial hypertension

El iloprost inhalado es un fármaco del grupo de las prostaciclinas utilizado en el tratamiento de la hipertensión arterial pulmonar. La eficacia y seguridad de su administración han permitido su uso como monoterapia y en terapia combinada. En esta revisión se describen las características del medicamento, los grupos susceptibles de tratamiento y la evidencia clínica actualizada del uso del fármaco.

Inhaled iloprost is a drug from the group of prostacyclins used in the treatment of pulmonary arterial hypertension. Its efficacy and safety have allowed its use as monotherapy and combination therapy. This review describes the product characteristics, amenable to treatment groups, and updated clinical evidence of drug use.

[Clinical utility of inhaled iloprost in pulmonary arterial hypertension]. / Utilidad clínica del iloprost inhalado en la hipertensión arterial pulmonar.

Inhaled iloprost is a drug from the group of prostacyclins used in the treatment of pulmonary arterial hypertension. Its efficacy and safety have allowed its use as monotherapy and combination therapy. This review describes the product characteristics, amenable to treatment groups, and updated clinical evidence of drug use.

Impacto do ecocardiograma transesofágico intraoperatório na mortalidade em cirurgia de revascularização do miocárdio com circulação extracorpórea / Impact of intraoperative transesophageal echocardiography in mortality in coronary artery bypass grafting

OBJETIVO: avaliar as taxas de mortalidade e morbidade de doentes submetidos à revascularização do miocárdio (RVM) com circulação extracorpórea (CEC) que utilizaram rotineiramente o ecocardiograma transesofágico intraoperatório (ETEio). MÉTODOS: estudo retrospectivo, observacional com avaliação de prontuários de 360 doentes no período entre abril de 2010 a abril de 2012. Foram analisados: idade, peso, altura sexo, EUROscore, diabete melito, fração de ejeção e artérias acometidas. Os desfechos foram compilados no intra e no pós-operatório (infarto do miocárdio, acidente vascular cerebral, disfunção renal, hemodiálise, fibrilação atrial, tempo de internação no centro de tratamento intensivo). RESULTADOS: foram incluídos 53 doentes, com 27 recebendo a monitoração. Foram excluídos 307 porque não foram operados pela mesma equipe cirúrgica. Os dois grupos foram homogêneos quanto a idade, peso e sexo, porém, a fração ejeção foi menor no grupo que recebeu o ecotransesofágico (G ETEio: 56,3%; G Não ETEio: 65,9% ± 11; p=0,01). Nos doentes em que não foi utilizado o ETEio, a mortalidade foi maior (G ETEio: 0% e G Não ETEio: 7,6%; p=0,01). Não houve diferença significativa entre os grupos quanto à incidência de acidente vascular encefálico, infarto agudo do miocárdio, fibrilação atrial aguda e lesão renal. CONCLUSÃO: a utilização do ecocardiograma transesofágico intraoperatório em pacientes submetidos à revascularização do miocárdio, com circulação extracorpórea, diminuiu a mortalidade perioperatória; orientou quanto a utilização dos fármacos inotrópicos e vasodilatadores e contribuiu para uma melhor evolução dos doentes.

OBJECTIVE: To evaluate the rates of mortality and morbidity in patients undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) using routine intraoperative transesophageal echocardiography (ITEE). METHODS: We conducted a retrospective, observational review of medical records of 360 patients from April 2010 to April 2012. We analyzed: age, weight, height, gender, EuroSCORE, diabetes mellitus, ejection fraction and number of diseased vessels. Outcomes were compiled in intraoperative and postoperative (myocardial infarction, stroke, renal failure, hemodialysis, atrial fibrillation, length of stay in the intensive care unit). RESULTS: 53 patients were included, with 27 receiving monitoring; we excluded 307 individuals, as they were not operated by the same surgical team. The two groups were homogeneous for age, weight and gender. However, the ejection fraction was lower in the group submitted to ITEE (ITEE group 56.3% versus Non-ITEE group 65.9 ± 11%, p = 0.01). In patients not subjected to ITEE, mortality was higher (ITEE group 0% versus Non-ITEE group 7.6%, p = 0.01). There was no significant difference between groups as for the incidence of stroke, myocardial infarction, atrial fibrillation and acute kidney injury. CONCLUSION: The use of intraoperative transesophageal echocardiography in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass decreased perioperative mortality, warranted the use of inotropic drugs and vasodilators and contributed to a better patient outcome.

Hipertensão pulmonar persistente neonatal: recentes avanços na fisiopatologia e tratamento / Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment

OBJETIVOS: Embora reconhecida há décadas, ainda pouco se sabe a respeito da etiologia, fisiopatologia e prevenção da hipertensão pulmonar persistente neonatal (HPPN), e seu tratamento continua a ser um grande desafio para os neonatologistas. Nesta revisão, vamos abordar as características clínicas e os mecanismos fisiopatológicos da síndrome, assim como seu tratamento geral e específico. FONTES DE DADOS: Fizemos uma revisão nas bases de dados PubMed, Cochrane Library e MRei Consult , procurando por artigos relacionados à síndrome e publicados entre 1995 e 2011. SÍNTESE DE DADOS: São discutidos os fatores de risco e os mecanismos fisiopatológicos da síndrome. O quadro clínico depende dos diferentes fatores envolvidos, que provavelmente estão relacionados com a etiologia e o mecanismo fisiopatológico. Além das medidas utilizadas para permitir a queda da resistência vascular pulmonar após o nascimento, alguns casos necessitam de vasodilatadores pulmonares. Embora o óxido nítrico tenha se provado efetivo, recentemente, outros vasodilatadores têm sido usados, mas ainda faltam evidências clínicas para comprovar seus benefícios no tratamento da HPPN. CONCLUSÕES: Apesar dos recentes avanços tecnológicos e dos novos conhecimentos fisiopatológicos, a mortalidade associada à HPPN ainda é de 10%. São necessárias mais pesquisas clínicas e resultados experimentais baseados em evidências para prevenir, tratar e reduzir a morbimortalidade associada a esta síndrome neonatal.

OBJECTIVES: Although recognized for decades, little is known about the etiology, physiopathology, and prevention of persistent pulmonary hypertension of the newborn (PPHN). and its treatment remains a major challenge for neonatologists. In this review, the clinical features and physiopathology of the syndrome will be addressed, as well as its general and specific treatments. DATA SOURCE: A review was carried out in PubMed, Cochrane Library, and MRei consult databases, searching for articles related to the syndrome and published between 1995 and 2011. DATA SYNTHESIS: Risk factors and the physiopathological mechanisms of the syndrome are discussed. The clinical picture depends on the different factors involved, which are probably related to the etiology and physiopathological mechanisms. In addition to the measures used to allow the decrease in pulmonary vascular resistance after birth, some cases will require pulmonary vasodilators. Although nitric oxide has proved effective, other vasodilators have been recently used, but clinical evidence is still lacking to demonstrate their benefits in the treatment of PPHN. CONCLUSIONS: Despite recent technological advances and new physiopathological knowledge, mortality associated with PPHN remains at 10%. More clinical research and evidence-based experimental results are needed to prevent, treat, and reduce the morbidity/mortality associated with this neonatal syndrome.

Efeito da cafeína na detecção de isquemia à cintilografia de perfusão miocárdica associada ao estresse com adenosina / Effects of caffeine on ischemia detection in myocardial perfusion scyntigraphy induced by adenosine stress

A utilização da cintilografia de perfusão miocárdica (CPM) estava limitada a pacientes que podiam realizar algum tipo de exercício, para ampliarmos a disponibilidade clínica da CPM, vários protocolos com estresses farmacológicos foram desenvolvidos. A adenosina fármaco amplamente utilizado, potente vasodilatador coronariano, apresenta uma importante interação com outras substâncias que anatagonizam seus efeitos, o dipiridamol, alimentos com cafeína e derivados de xantinas. O tempo de suspensão de cafeína da dieta para o uso exógeno da adenosina na realização da CPM ainda não está definido. Para testar essa hipótese avaliamos a influência da abstinência de cafeína em 24h, 12h e 1h, através de sua dosagem sérica, antes do estresse farmacológico com adenosina e sua possível repercussão nas imagens da CPM e o efeito vasodilatador no sistema cardiovascular. Definimos como objetivo primário: comparar a presença e a extensão dos defeitos reversíveis da CPM verificados em pacientes com abstinência de café por 24 horas (E1) com as imagens da randomização com 1 hora e 12 horas (E2) sem cafeína e como objetivos secundários: avaliar a presença e intensidade dos paraefeitos, comportamento da frequência cardíaca e da pressão arterial sistêmica. Foram submetidos ao estresse farmacológico com adenosina 194 pacientes para a realização da CPM, dos quais 43 pacientes preencheram os critérios para a randomização (defeitos perfusionais transitórios na CPM com adenosina). Excluímos seis pacientes (13,9%), três (6,9%) se recusaram a realizar a fase da randomização e os outros três (6,9%) nos quais não houve consenso entre os observadores em relação aos defeitos de perfusionais transitórios. A média de idade dos 37 pacientes analisados foi de 61,4 ± 8,3 anos, sendo 21 pacientes do sexo masculino (56,8%). Na avaliação das imagens da CPM, não houve diferença entre as imagens obtidas no grupo E1 comparadas as imagens de 1 (2,0 ± 1,5) hora ou 12 (12,6 ± 3,1) horas sem cafeína (E2)...

Myocardial perfusion imaging (MPI) in the past was only available to patients who were able to perform some type of exercise. Many protocols were developed with pharmacologic stress in order to enlarge the clinical availability of myocardial perfusion imaging (MPI). Adenosine is widely used and a potent coronary vasodilator, exhibits a significant interaction with other substances which antagonize its effects, such as dipyridamole, food products containing caffeine and xanthine derivatives. We found no clear consensus as to the time between caffeine ingestion and a cardiovascular adenosine stress test. To test this hypothesis we evaluated the influence of 24-hour, 12-hour and 1-hour caffeine abstinence, by assessing plasma caffeine levels before adenosine pharmacological stress, the possible repercussions on MPI images and vasodilatory effects on the cardiovascular system. The primary endpoint was to compare the presence and extent of reversible myocardial perfusion defects found in patients with 24-hour abstinence from coffee (E1), with images from patients randomized to 1-hour or 12-hour caffeine abstinence (E2). As secondary endpoints we evaluated the presence and intensity of paraeffects, as well as heart rate and systemic arterial blood pressure behavior. For this purpose, 194 patients underwent pharmacological stress with adenosine for MPI, 43 of whom fulfilled criteria for randomization (patients with transient perfusion defects detected on adenosine MPI). Six patients were excluded (13.9%), three patients (6.9%) who refused to undergo randomization, and other three (6.9%) in whom the observers could not reach consensus regarding transient perfusion defects. Mean age for the 37 patients analyzed was 61.4 ± 8.3 years, 21 patients male (56.8%). In the evaluation of myocardial perfusion images, no differences were detected between images obtained in the 24-hour E1 arm, and those from 1 (2.0 ± 1.5) hour or 12 (12.6 ± 3.1) hours...

Vasodilator activity of extracts of field Alpinia purpurata (Vieill) K: Schum and A. zerumbet (Pers.) Burtt et Smith cultured in vitro / Vasodilatador de extratos de Alpinia purpurata campo (Vieill) K. Schum e A. zerumbet (Pers.) Burtt et Smith cultivadas in vitro

Nowadays, the high blood pressure is one of the main causes of death and cardiovascular diseases. Vasodilator drugs are frequently used to treat arterial hypertension. Experiments were undertaken to determine whether hydroalcoholic extracts obtained from leaves of field-grown Alpinia purpurata and A. zerumbet cultured in vitro under different plant growth regulators induce a vasodilator effect on Wistar rat mesenteric vascular bed pre-contracted with norepinephrine. Plant extracts were able to induce a long-lasting endothelium-dependent vasodilation. Efficiency on activity of A. purpurata reached 87 percent at concentration of 60 μg. The extract of A. zerumbet maintained in medium containing IAA, induced the relaxation (17.4 percent) at 90 μg, as compared to the control (MS0) that showed a better vasodilator effect (60 percent). These results are in agreement with the quantification of phenolic compounds in the extracts, which were 50 percent lower for those plants cultured in IAA. A. purpurata was assayed for the first time in relation to its vasodilator activity. This paper showed a strong probability of correlation between the pharmacological activities of A. purpurata with their content in phenolic compounds.

Atualmente, a hipertensão arterial é uma das maiores causas de morte e de doenças cardiovasculares. Os vasodilatadores são freqüentemente utilizados no tratamento da hipertensão. Extratos hidroalcoólicos de Alpinia purpurata de campo e de A. zerumbet cultivada in vitro sob diferentes reguladores de crescimento vegetal foram ensaiados no leito mesentérico de ratos Wistar. Os extratos de A. purpurata e A. zerumbet produziram efeito vasodilatador com padrão de resposta dose-dependente de duração prolongada. Extratos da espécie A. purpurata tiveram efeito vasodilatador de 87 por cento na dose de 60 μg. O extrato obtido de folhas de A. zerumbet oriundas das culturas mantidas em meio contendo AIA (ácido indol acético) inibiu o relaxamento (17,4 por cento) na dose de 90 μg em relação ao controle (MS0), com o qual foi verificado melhor efeito vasodilatador (60 por cento). Estes resultados estão de acordo com a concentração de fenóis totais que foi 50 por cento menor para os extratos de plantas cultivadas in vitro em AIA. A espécie A. purpurata foi pela primeira vez ensaiada quanto à atividade vasodilatadora. Os resultados obtidos indicaram a presença de substâncias fenólicas provavelmente correlacionadas à ação terapêutica de A. purpurata.

Nitroglicerina transdérmica em portadores de angina estável / Nitroglycerin patches in patients with stable angina

Objetivo - Avaliar os efeitos clínicos da nitroglicerina transdérmica em portadores de angina estável. Métodos - Quinhentos e trinta e cinco especialistas avaliaram mil quinhentos e trinta e nove pacientes com angina estável, idade média de 61,0 ñ 10,3 anos, sendo 891 (57,97%) do sexo masculino. O estudo multicêntrico prospectivo consistiu na aplicaçäo inicial de 5 mg e, após duas semanas, caso persistisse quadro de angina ou infradesnivelamanto de ST, a dose era aumentada para 10 mg de nitroglicerina transdérmica, a cada 12-14 horas, por 12 semanas. Foram realizadas avaliaçöes clínicas no período inicial e nas semanas 2, 4, 8 e 12, e eletrocardiograma e eletrocardiograma de esforço (ECGE), no início e na 12ª semana. Resultados - Observou-se reduçäo estatisticamente significante (p < 0,005) no número de crises anginosas, no consumo de nitratos sublingual, na pressäo arterial e na porcentagem de pacientes com ECGE isquêmico. A frequência cardíaca e a dose de nitroglicerina transdérmica utilizada näo tiveram alteraçöes significativas. A tolerabilidade desta via de administraçäo foi considerada muito boa e boa em 92,2% dos pacientes. Conclusäo - A utilizaçäo da nitroglicerina transdérmica mostrou-se eficaz no tratamento da angina estável, com excelente tolerabilidade pelo paciente

Purpose - To evaluate the nitroglycerin patches efficacy and tolerability in patients with stable angina pectoris. Methods - One thousand and five hundred and thirty nine patients with stable angina pectoris, mean age 61.0 + 10.3, 891 men and 648 women were prospectively evaluated by five hundred and thirty five specialists after 5 mg or, posteriorly, if clinical necessary, 10 mg of nitroglycerin patches during 12 weeks. Clinical evaluation, electrocardiogram (ECG) and treadmill exercise were obtained on study entry and at weeks 2, 4, 8 and 12 for clinical evaluation, and at week 12 for ECG and treatmill exercise. Results - A significative reduction was observed in the number of angina crisis, sublingual nitrates consumption, arterial blood pressure and on the percentage of positive treadmill exercise tests. The heart rate and nitroglycerin patches dose did not show statistical differences. The compliance of transdermal administration was excellent. Conclusion - The nitroglycerin patches administration was effective for stable angina pectoris with excellent patient's compliance